These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20843437)

  • 1. [Comparison of plasma matrix metalloproteases 2, 3, 9 in breast carcinomas and fibroadenomas].
    Solai F; Nardo T; Patrizi G; Annessi M; Santulli M; Amabile MI; Vasaturo F
    G Chir; 2010; 31(8-9):365-7. PubMed ID: 20843437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma concentration and activity of matrix metalloproteinase 2 and 9 in patients with breast disease, breast cancer and at risk of developing breast cancer.
    Somiari SB; Shriver CD; Heckman C; Olsen C; Hu H; Jordan R; Arciero C; Russell S; Garguilo G; Hooke J; Somiari RI
    Cancer Lett; 2006 Feb; 233(1):98-107. PubMed ID: 16473671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
    Sliwowska I; Kopczyński Z
    Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.
    Di Carlo A; Terracciano D; Mariano A; Macchia V
    Int J Oncol; 2005 May; 26(5):1363-8. PubMed ID: 15809729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas.
    Lebeau A; Nerlich AG; Sauer U; Lichtinghagen R; Löhrs U
    Anticancer Res; 1999; 19(5B):4257-64. PubMed ID: 10628384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative determination of telomerase activity in breast cancer and benign breast diseases.
    Simícková M; Nekulová M; Pecen L; Cernoch M; Vagundová M; Pacovský Z
    Neoplasma; 2001; 48(4):267-73. PubMed ID: 11712677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
    Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
    Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
    Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
    Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas.
    Ueno H; Nakamura H; Inoue M; Imai K; Noguchi M; Sato H; Seiki M; Okada Y
    Cancer Res; 1997 May; 57(10):2055-60. PubMed ID: 9158005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer.
    Shah FD; Shukla SN; Shah PM; Shukla HK; Patel PS
    Indian J Cancer; 2009; 46(3):194-202. PubMed ID: 19574670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma.
    Wong TS; Kwong DL; Sham JS; Wei WI; Kwong YL; Yuen AP
    Eur J Surg Oncol; 2004 Jun; 30(5):560-4. PubMed ID: 15135487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression.
    Patel S; Sumitra G; Koner BC; Saxena A
    Clin Biochem; 2011 Jul; 44(10-11):869-72. PubMed ID: 21565179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip.
    Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y
    Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their tissue natural inhibitors in breast tumors.
    Jinga D; Stefanescu M; Blidaru A; Condrea I; Pistol G; Matache C
    Roum Arch Microbiol Immunol; 2004; 63(3-4):141-58. PubMed ID: 17240786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
    Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
    Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer.
    Daniele A; Zito AF; Giannelli G; Divella R; Asselti M; Mazzocca A; Paradiso A; Quaranta M
    Anticancer Res; 2010 Sep; 30(9):3521-7. PubMed ID: 20944132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.